BiotechTube

Lanreotide + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoid Syndrome

Conditions

Carcinoid Syndrome

Trial Timeline

May 1, 2009 → Dec 1, 2015

NCT ID
NCT00774930

About Lanreotide + Placebo

Lanreotide + Placebo is a phase 3 stage product being developed by Ipsen for Carcinoid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00774930. Target conditions include Carcinoid Syndrome.

What happened to similar drugs?

1 of 8 similar drugs in Carcinoid Syndrome were approved

Approved (1) Terminated (1) Active (6)
✅lanreotide (Autogel formulation)IpsenApproved
🔄Pasireotide + OctreotideNovartisPhase 3
🔄Octreotide + Placebo + EverolimusNovartisPhase 3
❌lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
🔄Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
🔄Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3
🔄Telotristat etiprateLexicon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00774930Phase 3Completed

Competing Products

20 competing products in Carcinoid Syndrome

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Somatostatin AnalogEli LillyPhase 2
35
PasireotideNovartisPhase 1
29
Pasireotide + OctreotideNovartisPhase 3
40
Pasireotide (SOM230)NovartisPhase 2
35
Octreotide + Placebo + EverolimusNovartisPhase 3
40
LutatheraNovartisPhase 2
27
EPO906 epothilone BNovartisPhase 2
35
PanitumumabAmgenPhase 2
27
AxitinibPfizerPhase 2
35
Lanreotide + Placebo (for sunitinib) + SunitinibPfizerPhase 2
31
Nivolumab + CabozantinibBristol Myers SquibbPhase 2
35
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatinSanofiPhase 2/3
30
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
29
lanreotide (Autogel formulation)IpsenApproved
40
BIM 23A760IpsenPhase 2
24
Randomized: 40 mg Paltusotine + Randomized: 80 mg PaltusotineCrinetics PharmaceuticalsPhase 2
32
Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
44
Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3
34
Telotristat etiprateLexicon PharmaceuticalsPhase 3
34
500 mg [14C]-LX1606Lexicon PharmaceuticalsPhase 1
23